Acadia Pharmaceuticals Shares Fall as ACP-101 Trial Misses Primary Endpoint

Acadia's experimental drug, ACP-101 (intranasal carbetocin), designed to treat extreme hunger (hyperphagia) in Prader-Willi syndrome patients, did not meet its main goal in the recent Phase 3 trial.